Asia-Pacific: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Asia-Pacific

The Asia-Pacific prophylactic medicaments containing insulin market rose significantly to $X in 2023, growing by X% against the previous year. Over the period under review, consumption saw a noticeable shrinkage. As a result, consumption reached the peak level of $X. From 2017 to 2023, the growth of the market remained at a lower figure.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Asia-Pacific

In value terms, prophylactic medicaments containing insulin production rose notably to $X in 2023 estimated in export price. Overall, production, however, recorded prominent growth. The growth pace was the most rapid in 2021 with an increase of X%. As a result, production attained the peak level of $X. From 2022 to 2023, production growth remained at a lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports in Asia-Pacific

In 2023, after two years of growth, there was significant decline in overseas shipments of medicaments containing insulin but not antibiotics in measured doses, when their volume decreased by X% to X tons. Over the period under review, exports, however, saw a relatively flat trend pattern. The pace of growth appeared the most rapid in 2013 when exports increased by X%. As a result, the exports attained the peak of X tons. From 2014 to 2023, the growth of the exports remained at a somewhat lower figure.

In value terms, prophylactic medicaments containing insulin exports shrank markedly to $X in 2023. In general, exports, however, posted a strong expansion. The most prominent rate of growth was recorded in 2021 when exports increased by X%. As a result, the exports attained the peak of $X. From 2022 to 2023, the growth of the exports remained at a lower figure.

Exports by Country

India was the key exporter of medicaments containing insulin but not antibiotics in measured doses in Asia-Pacific, with the volume of exports recording X tons, which was near X% of total exports in 2023. Malaysia (X tons) held a X% share (based on physical terms) of total exports, which put it in second place, followed by China (X%). Singapore (X tons) held a minor share of total exports.

From 2012 to 2023, average annual rates of growth with regard to prophylactic medicaments containing insulin exports from India stood at X%. At the same time, Singapore (X%), Malaysia (X%) and China (X%) displayed positive paces of growth. Moreover, Singapore emerged as the fastest-growing exporter exported in Asia-Pacific, with a CAGR of X% from 2012-2023. Malaysia (X p.p.), China (X p.p.) and Singapore (X p.p.) significantly strengthened its position in terms of the total exports, while India saw its share reduced by X% from 2012 to 2023, respectively.

In value terms, the largest prophylactic medicaments containing insulin supplying countries in Asia-Pacific were China ($X), India ($X) and Malaysia ($X), with a combined X% share of total exports.

Among the main exporting countries, Malaysia, with a CAGR of X%, saw the highest growth rate of the value of exports, over the period under review, while shipments for the other leaders experienced more modest paces of growth.

Export Prices by Country

In 2023, the export price in Asia-Pacific amounted to $X per ton, with a decrease of X% against the previous year. Overall, the export price, however, showed a strong increase. The pace of growth appeared the most rapid in 2015 an increase of X%. Over the period under review, the export prices attained the peak figure at $X per ton in 2021; however, from 2022 to 2023, the export prices failed to regain momentum.

Prices varied noticeably by country of origin: amid the top suppliers, the country with the highest price was Singapore ($X per ton), while India ($X per ton) was amongst the lowest.

From 2012 to 2023, the most notable rate of growth in terms of prices was attained by Malaysia (X%), while the other leaders experienced more modest paces of growth.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports in Asia-Pacific

In 2023, supplies from abroad of medicaments containing insulin but not antibiotics in measured doses decreased by X% to X tons, falling for the third year in a row after three years of growth. The total import volume increased at an average annual rate of X% from 2012 to 2023; however, the trend pattern indicated some noticeable fluctuations being recorded in certain years. The most prominent rate of growth was recorded in 2019 with an increase of X% against the previous year. Over the period under review, imports hit record highs at X tons in 2020; however, from 2021 to 2023, imports failed to regain momentum.

In value terms, prophylactic medicaments containing insulin imports declined rapidly to $X in 2023. In general, imports recorded a noticeable descent. The pace of growth was the most pronounced in 2016 when imports increased by X% against the previous year. The level of import peaked at $X in 2021; however, from 2022 to 2023, imports failed to regain momentum.

Imports by Country

In 2023, Japan (X tons), followed by Pakistan (X tons), India (X tons), Malaysia (X tons), Australia (X tons), Indonesia (X tons), Thailand (X tons), Singapore (X tons), the Philippines (X tons), South Korea (X tons) and Vietnam (X tons) represented the major importers of medicaments containing insulin but not antibiotics in measured doses, together making up X% of total imports.

From 2012 to 2023, the most notable rate of growth in terms of purchases, amongst the main importing countries, was attained by Malaysia (with a CAGR of X%), while imports for the other leaders experienced more modest paces of growth.

In value terms, Japan ($X), India ($X) and Australia ($X) constituted the countries with the highest levels of imports in 2023, with a combined X% share of total imports. South Korea, Indonesia, Vietnam, Singapore, Pakistan, the Philippines, Malaysia and Thailand lagged somewhat behind, together accounting for a further X%.

Among the main importing countries, Malaysia, with a CAGR of X%, recorded the highest rates of growth with regard to the value of imports, over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

In 2023, the import price in Asia-Pacific amounted to $X per ton, declining by X% against the previous year. Overall, the import price showed a deep contraction. The pace of growth was the most pronounced in 2021 when the import price increased by X%. The level of import peaked at $X per ton in 2012; however, from 2013 to 2023, import prices stood at a somewhat lower figure.

Prices varied noticeably by country of destination: amid the top importers, the country with the highest price was India ($X per ton), while Malaysia ($X per ton) was amongst the lowest.

From 2012 to 2023, the most notable rate of growth in terms of prices was attained by Pakistan (X%), while the other leaders experienced more modest paces of growth.

Source: IndexBox Platform